ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of ADC Therapeutics SA (NYSE:ADCT) have received an average rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $7.50.

A number of research analysts recently commented on ADCT shares. Guggenheim reiterated a “buy” rating and set a $10.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, November 12th. Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st. HC Wainwright decreased their target price on ADC Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, October 16th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $5.00 target price on shares of ADC Therapeutics in a report on Wednesday, December 3rd.

ADC Therapeutics Stock Performance

Shares of ADCT opened at $4.00 on Friday. ADC Therapeutics has a one year low of $1.05 and a one year high of $4.80. The stock’s fifty day moving average is $3.73 and its 200-day moving average is $3.68. The firm has a market capitalization of $495.52 million, a price-to-earnings ratio of -2.76 and a beta of 1.93.

ADC Therapeutics (NYSE:ADCT) last announced its earnings results on Monday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.10. The company had revenue of $16.43 million during the quarter, compared to the consensus estimate of $17.08 million. Analysts forecast that ADC Therapeutics will post -1.69 EPS for the current fiscal year.

Institutional Trading of ADC Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC grew its position in ADC Therapeutics by 27.0% in the fourth quarter. ProShare Advisors LLC now owns 15,727 shares of the company’s stock worth $56,000 after buying an additional 3,339 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of ADC Therapeutics by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 32,502 shares of the company’s stock worth $130,000 after acquiring an additional 7,701 shares during the last quarter. R Squared Ltd acquired a new position in shares of ADC Therapeutics in the 3rd quarter worth $59,000. Henrickson Nauta Wealth Advisors Inc. acquired a new stake in shares of ADC Therapeutics during the fourth quarter worth $69,000. Finally, SG Americas Securities LLC purchased a new stake in shares of ADC Therapeutics during the fourth quarter valued at $86,000. 41.10% of the stock is owned by institutional investors and hedge funds.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.